Selected article for: "antiviral treatment and hepatocellular carcinoma cirrhosis"

Author: Drexler, Jan Felix; Corman, Victor Max; Müller, Marcel Alexander; Lukashev, Alexander N.; Gmyl, Anatoly; Coutard, Bruno; Adam, Alexander; Ritz, Daniel; Leijten, Lonneke M.; van Riel, Debby; Kallies, Rene; Klose, Stefan M.; Gloza-Rausch, Florian; Binger, Tabea; Annan, Augustina; Adu-Sarkodie, Yaw; Oppong, Samuel; Bourgarel, Mathieu; Rupp, Daniel; Hoffmann, Bernd; Schlegel, Mathias; Kümmerer, Beate M.; Krüger, Detlev H.; Schmidt-Chanasit, Jonas; Setién, Alvaro Aguilar; Cottontail, Veronika M.; Hemachudha, Thiravat; Wacharapluesadee, Supaporn; Osterrieder, Klaus; Bartenschlager, Ralf; Matthee, Sonja; Beer, Martin; Kuiken, Thijs; Reusken, Chantal; Leroy, Eric M.; Ulrich, Rainer G.; Drosten, Christian
Title: Evidence for Novel Hepaciviruses in Rodents
  • Document date: 2013_6_20
  • ID: 1v353uij_1
    Snippet: Hepatitis C virus is one of the leading causes of human morbidity and mortality due to hepatitis, liver cirrhosis, and hepatocellular carcinoma [1, 2, 3] . It has become the main reason for liver transplantation in developed countries and represents an economic burden exceeding 1 billion US$ of direct health costs [4, 5] . New estimates of the burden of disease suggest at least 185 million individuals worldwide to have been seropositive in 2005, .....
    Document: Hepatitis C virus is one of the leading causes of human morbidity and mortality due to hepatitis, liver cirrhosis, and hepatocellular carcinoma [1, 2, 3] . It has become the main reason for liver transplantation in developed countries and represents an economic burden exceeding 1 billion US$ of direct health costs [4, 5] . New estimates of the burden of disease suggest at least 185 million individuals worldwide to have been seropositive in 2005, with a tendency to increase [6] . Treatment has considerably improved due to the optimization of antiviral regimens and the advent of new antiviral drugs [7, 8, 9] . However, treatment in resource-limited settings is hardly accessible [10] . The most effective instrument to prevent new infections with HCV would be a prophylactic vaccine. Unfortunately, chimpanzees are the only known animal species to adequately reflect human HCV infection [11] . Vaccine development is hampered by the lack of a small animal model accessible at early stages of vaccine development [12, 13] . Mice cannot be infected with HCV [14] , but rats and mice engrafted with human hepatoma cells or transgenic for human CD81 and other co-receptor molecules have been proposed [12, 15, 16, 17] . Mouse-adapted HCV has also been generated [16, 18] . Still, these models are highly demanding from a technical point of view and reflect only parts of the pathogenesis and lifecycle of HCV, precluding their wide application [12, 19] .

    Search related documents:
    Co phrase search for related documents
    • animal model and co receptor: 1
    • animal model and disease burden: 1, 2
    • animal model and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • animal model and economic burden: 1, 2, 3, 4
    • antiviral drug and disease burden: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • antiviral drug and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • antiviral drug and economic burden: 1, 2
    • antiviral regimen and early stage: 1
    • co receptor and early stage: 1, 2, 3
    • direct health cost and disease burden: 1, 2
    • direct health cost and economic burden: 1, 2
    • disease burden and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • disease burden and economic burden: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • early stage and economic burden: 1, 2, 3